Dulaglutide (Trulicity)
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Dulaglutide is a once-weekly GLP-1 receptor agonist marketed as Trulicity. It pairs a modified version of the human GLP-1 peptide with a fragment of an antibody (an IgG4-Fc region), joined by a short linker. This fusion design makes the molecule large enough to resist rapid breakdown and kidney clearance, which is what allows for once-weekly dosing.
It is FDA-approved to improve blood-sugar control in adults and pediatric patients aged 10 and older with type 2 diabetes, and in eligible adults it is also approved to lower the risk of major cardiovascular events. Unlike research-only peptides, dulaglutide is a fully approved prescription medicine with an established clinical evidence base.
As a GLP-1 receptor agonist, dulaglutide belongs to the same broad class as semaglutide and liraglutide, and it shares many of the same reported metabolic effects, including appetite suppression and modest weight loss.
How it works
Dulaglutide mimics glucagon-like peptide-1 (GLP-1), a hormone the gut releases after eating. By activating GLP-1 receptors, it enhances insulin secretion in a glucose-dependent way — meaning it tends to work when blood sugar is elevated — while suppressing inappropriate glucagon release from the pancreas, which reduces the liver’s glucose output.
It also slows gastric emptying and acts on appetite-regulating pathways, which is thought to contribute to reduced food intake. The IgG4-Fc carrier extends how long the molecule stays active in the body, supporting a once-weekly schedule.
Reported benefits
- Improved blood-sugar (HbA1c) control in type 2 diabetes (clinical trial data)
- Reduced risk of major cardiovascular events in at-risk adults (studied in the REWIND trial)
- Appetite suppression and modest weight loss commonly reported for the GLP-1 class
- Once-weekly dosing, which some people find more convenient than daily options
These are studied and reported effects, and individual outcomes vary.
Considerations & side effects
The most commonly reported side effects are gastrointestinal, including nausea, diarrhea, vomiting, and abdominal discomfort, which are often more noticeable when starting or increasing the dose. The FDA label carries a boxed warning about thyroid C-cell tumors observed in rodents; it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Reported risks also include pancreatitis and, when combined with insulin or sulfonylureas, low blood sugar.
Dulaglutide is a prescription medication and is not a substitute for evaluation and treatment by a qualified clinician, who can weigh its benefits and risks for an individual situation.
Frequently asked
What is dulaglutide?
A once-weekly GLP-1 receptor agonist built on an antibody (IgG4-Fc) fusion platform, marketed as Trulicity for the management of type 2 diabetes.
Is dulaglutide FDA-approved?
Yes. Dulaglutide is FDA-approved under the brand name Trulicity for improving blood sugar control in type 2 diabetes and, in eligible adults, for reducing the risk of major cardiovascular events.
How is dulaglutide different from other GLP-1 medications?
It fuses a modified GLP-1 peptide to an IgG4-Fc fragment, which slows clearance and supports once-weekly subcutaneous dosing via a single-dose pen.
Is dulaglutide used for weight loss?
It is approved for type 2 diabetes rather than as a dedicated weight-loss drug, but appetite reduction and modest weight loss are commonly reported effects in studies of GLP-1 receptor agonists.
References
Related compounds
Long-acting amylin receptor agonist for weight management. Combined with semaglutide in CagriSema, showing up to 22.7% weight loss in Phase III trials.
Weight blend combining the amylin analog cagrilintide with the GIP/GLP-1 dual agonist tirzepatide, targeting satiety and glycemic pathways together. No human trial of this exact combination; research-level, sold pre-blended.
Dual-mechanism weight blend pairing the long-acting amylin analog cagrilintide with the GLP-1 agonist semaglutide (1:1). Novo Nordisk's clinical program showed greater weight loss than either component alone. Sold as a single co-lyophilized vial.